retatrutide clinical trial results 2024 2025 retatrutide weight loss study type 2 diabetes phase 2 ada demonstrate benefits of in obesity, diabetes, NASH Efficacy and Safety of – Lilly's triple agonist achieves 16.8%

[10] [11] A direct causal link with retatrutide has not yet been formally established, but the risk cannot be excluded Right upper quadrant pain, fever, or jaundice (yellowing of the skin or eyes), which may suggest gallbladder disease (such as gallstones or cholecystitis) another recognised class-related risk Severe constipation with vomiting, abdominal distension, and inability to pass wind, which may indicate intestinal obstruction or ileus and requires urgent assessment Symptoms that feel disproportionate or different in character from typical digestive upset In an emergency, contact NHS 111 or attend your nearest accident and emergency department

Frequently asked questions How quickly does GHRP-6 start working

Similar content being viewed by others Introduction A progressive decline in skeletal muscle mass and strength, or sarcopenia, is increasingly recognized as a significant comorbidity in patients with type 2 diabetes mellitus (T2D) and obesity [1, 2]

As of early 2026, the TRIUMPH program is fully enrolled across most arms, with topline readouts expected on a staggered timeline